BDTX vs RVMD
BDTX: A clinical-stage oncology firm using its proprietary MasterKey platform to develop precision, brain-penetrant inhibitors that target families of oncogenic mutations. RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform.
Side-by-side fundamentals
| Metric | BDTX | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.07 | $196.55 | |
| Market cap | $119M | $42.1B | |
| ROE FY2025, SEC XBRL | +19.9% | -69.3% | BDTX higher |
| ROA FY2025, SEC XBRL | +15.6% | -48.0% | BDTX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.63 | 1.05 | |
| 1-year return as of 2026-10-20 close | -49.6% | +263.9% | RVMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.